89Zr-bevacizumab PET imaging in primary breast cancer

Journal of Nuclear Medicine

Volumn 54, Issue 7, 2013, Pages 1014-1018

  Gaykema, Sietske B M ^a   Brouwers, Adrienne H ^a   Hooge, Marjolijn N Lub De ^a   Pleijhuis, Rick G ^a   Timmer Bosscha, Hetty ^a   Pot, Linda ^a   Van Dam, Gooitzen M ^a   Van Der Meulen, Sibylle B ^a   De Jong, Johan R ^a   Bart, Joost ^a   De Vries, Jakob ^a   Jansen, Liesbeth ^a   De Vries, Elisabeth G E ^a   Schröder, Carolien P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

89Zr bevacizumab PET; Breast cancer; Early detection; VEGF A

Indexed keywords

BEVACIZUMAB; BEVACIZUMAB ZR 89; TRACER; UNCLASSIFIED DRUG; VASCULOTROPIN A; 89ZR BEVACIZUMAB; 89ZR-BEVACIZUMAB; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER; VEGFA PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST ADENOCARCINOMA; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MASTECTOMY; MOLECULAR IMAGING; PARTIAL MASTECTOMY; PET SCANNER; PHANTOM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR VOLUME; 89ZR-BEVACIZUMAB PET; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; EARLY DETECTION; FEASIBILITY STUDY; METABOLISM; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VEGF-A;

89ZR-BEVACIZUMAB PET; BREAST CANCER; EARLY DETECTION; VEGF-A;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879942864     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.117218     Document Type: Article

References (26)

1. Ferlay J, Shin HR, Bray F, Forman D,Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Vogl G, Bartel H, Dietze O, Hauser-Kronberger C. HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer. Appl Immunohistochem Mol Morphol. 2006;14:138-145.
3. Kostopoulos I, Arapantoni-Dadioti P, Gogas H, et al. Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Breast Cancer Res Treat. 2006;96:251-261.
4. Fuckar D, Dekanic A, Stifter S, et al. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer. Int J Surg Pathol. 2006;14:49-55.
5. Liu Y, Tamimi RM, Collins LC, et al. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study. Breast Cancer Res Treat. 2011;129:175-184.
6. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313-1319.
7. Nagengast WB, de Korte MA, Oude Munnink TH, et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVPAUY922. J Nucl Med. 2010;51:761-767.
8. Oosting SF, Brouwers AH, Van Es SC, et al. 89Zr-bevacizumab PET imaging in metastatic renal cell carcinoma patients before and during antiangiogenic treatment. J Clin Oncol. 2012;30(suppl): abstract 10581.
9. Nagengast WB, Hooge MN, van Straten EM, et al. VEGF-SPECT with 111Inbevacizumab in stage III/IV melanoma patients. Eur J Cancer. 2011;47:1595-1602.
10. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
11. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
12. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes: dealing with the diversity of breast cancer - highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-1747.
13. De Grand AM, Lomnes SJ, Lee DS, et al. Tissue-like phantoms for near-infrared fluorescence imaging system assessment and the training of surgeons. J Biomed Opt. 2006;11:014007.
14. Pleijhuis RG, Langhout GC, Helfrich W, et al. Near-infrared fluorescence (NIRF) imaging in breast-conserving surgery: assessing intraoperative techniques in tissue-simulating breast phantoms. Eur J Surg Oncol. 2011;37:32-39.
15. Bluff JE, Menakuru SR, Cross SS, et al. Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. Br J Cancer. 2009;101:666-672.
16. Toi M, Kondo S, Suzuki H, et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer. 1996;77:1101-1106.
17. Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29:4286-4293.
18. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
19. Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495-3502.
20. Veronesi U, De Cicco C, Galimberti VE, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2007;18:473-478.
21. O'Dey D, Prescher A, Pallua N. Vascular reliability of nipple-areola complexbearing pedicles: an anatomical microdissection study. Plast Reconstr Surg. 2007;119:1167-1177.
22. O'Connor MK, Li H, Rhodes DJ, Hruska CB, Clancy CB, Vetter RJ. Comparison of radiation exposure and associated radiation-induced cancer risks from mammography and molecular imaging of the breast. Med Phys. 2010;37:6187-6198.
23. de Jong JR, Warnders FJ, Nagengast WB, et al. Radiation dosimetry of 111Inbevacizumab for VEGF-SPECT in melanoma patients. Eur J Nucl Med Mol Imaging. 2010;37(suppl):S477-S477.
24. Börjesson PK, Jauw YW, de Bree R, et al. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50:1828-1836.
25. Murano T, Minamimoto R, Senda M, et al. Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET: results of a Japanese nationwide survey. Ann Nucl Med. 2011;25:657-666.
26. Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, et al. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med. 2011;52:1778-1785.